Eugia receives FDA approval for Amiodarone HCl Injection!
Published: October 26, 2017
On October 25, 2017 Eugia received FDA approval for Amiodarone HCl Injection which is an antiarrhythmic indicated as the initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (and hemodynamically unstable ventricular tachycardia) in patients refractory to other therapy.
According to IMS data annual reporting through June 2017, the market size of this product is estimated at $8 million.